We don’t need to change how we subsidise ‘breakthrough’ cancer treatments

New therapies that arm the immune system to fight cancer, such as Keytruda (pembrolizumab) and Yervoy (ipilimumab), have offered patients with advanced melanoma real hope of effective treatment. But until these drugs, known as immunotherapies, were publicly subsidised, they were prohibitively expensive for Australian patients. A patient using Keytruda, for example, would be out of ...

Already a member?

Login to keep reading.

© 2021 the limbic